PharmacyCodes



Oxaliplatinum [Latin] en es it fr

Categoria

Oxaliplatinum [Latin] Nombres de marca, Oxaliplatinum [Latin] Analogos

Oxaliplatinum [Latin] Marca los nombres de mezcla

  • No information avaliable

    • Oxaliplatinum [Latin] Formula quimica

    C8H12N2O4Pt

    Oxaliplatinum [Latin] RX enlace

    http://www.rxlist.com/cgi/generic/eloxatin.htm

    Oxaliplatinum [Latin] FDA hoja

    Oxaliplatinum_[Latin] FDA

    Oxaliplatinum [Latin] MSDS (hoja de seguridad de materiales)

    Oxaliplatinum_[Latin] MSDS

    Oxaliplatinum [Latin] Sintesis de referencia

    No hay información disponible

    Oxaliplatinum [Latin] Peso molecular

    395.27 g/mol

    Oxaliplatinum [Latin] Punto de fusion

    No information avaliable

    Oxaliplatinum [Latin] H2O Solubilidad

    No hay información disponible

    Oxaliplatinum [Latin] Estado

    Solid

    Oxaliplatinum [Latin] LogP

    No information avaliable

    Oxaliplatinum [Latin] Formas de dosificacion

    No hay información disponible

    Oxaliplatinum [Latin] Indicacion

    Para el tratamiento de neoplasias malignas de colon, recto y ovario

    Oxaliplatinum [Latin] Farmacologia

    Oxaliplatino inhibe selectivamente la síntesis del ácido desoxirribonucleico (ADN). El contenido de guanina y citosina se correlaciona con el grado de oxaliplatino inducida por entrecruzamiento. En altas concentraciones de la droga, el ARN celular y la síntesis de proteínas también se suprimen.

    Oxaliplatinum [Latin] Absorcion

    No hay información disponible

    Oxaliplatinum [Latin] Toxicidad

    No hay información disponible

    Oxaliplatinum [Latin] Informacion de Pacientes

    Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.

    Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.

    Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.

    Oxaliplatinum [Latin] Organismos afectados

    Humanos y otros mamíferos